Evidence map›Paper›PMID 42412123›Full record

ArticleCellular and molecular life sciences : CMLS2026

SHIP1 is required for T cell surveillance of occult malignancies.

S Fernandes, N Srivastava, C Pedicone, R Sudan, R W Engelman, W G Kerr

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cellular and molecular life sciences : CMLS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

S Fernandes *Department of Microbiology & Immunology, SUNY Upstate Medical University, Syracuse, NY, USA.
N Srivastava *Department of Microbiology & Immunology, SUNY Upstate Medical University, Syracuse, NY, USA.
C Pedicone *Department of Microbiology & Immunology, SUNY Upstate Medical University, Syracuse, NY, USA.
R SudanDepartment of Microbiology & Immunology, SUNY Upstate Medical University, Syracuse, NY, USA.
R W Engelman *Departments of Pathology & Cell Biology and Pediatrics, H. Lee Moffitt Comprehensive Cancer Center and Research Institute, University of South Florida, Tampa, FL, USA.
W G Kerr *Department of Microbiology & Immunology, SUNY Upstate Medical University, Syracuse, NY, USA. wgkerr@mac.com.ORCID http://orcid.org/0000-0002-4720-7135

Funding

Translating SHIP1 Genetics to Generate a Novel Alzheimers Pharmacologic AgentRF1AG059717 · NIA · UNIVERSITY OF KENTUCKY · PI ESTUS, STEVEN, HUMPHREY, MARY BETH · 2018 to 2019
$3.9M
Alzheimer's Association E2A-24-1145198NIA NIH HHS RF1 AG059717NIA NIH HHS RO1 AG059717
6 · The paper itself

Abstract

SHIP1-deficient mice develop severe, transmural Crohn's-like ileitis and die prematurely. Recent analysis of a human Crohn's disease (CD) cohort revealed a significant subset of patients have severely reduced levels of SHIP1 expression suggesting SHIP1 deficiency leads to CD in both rodents and humans. The mucosal inflammatory disease that causes the premature death of SHIP1

Indexed as

Intestinal NeoplasmsPhosphatidylinositol-3,4,5-Trisphosphate 5-PhosphatasesT-LymphocytesAnimalsCrohn DiseaseHumansMiceMice, Inbred C57BLMice, KnockoutInpp5d protein, mousePhosphatidylinositol-3,4,5-Trisphosphate 5-PhosphatasesEpithelial adenocarcinomaHistiosarcomaIntestinal lymphoid tissuePeyer's patchSHIP1/Inpp5dT cellsTumor immunosurveillance

Identifiers

PMID42412123
PMCPMC13627489

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.